JP2019529385A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529385A5
JP2019529385A5 JP2019512292A JP2019512292A JP2019529385A5 JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5 JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5
Authority
JP
Japan
Prior art keywords
use according
mammal
cells
cns
therapeutic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512292A
Other languages
English (en)
Japanese (ja)
Other versions
JP7610923B2 (ja
JP2019529385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049959 external-priority patent/WO2018045347A1/en
Publication of JP2019529385A publication Critical patent/JP2019529385A/ja
Publication of JP2019529385A5 publication Critical patent/JP2019529385A5/ja
Priority to JP2022002163A priority Critical patent/JP2022050574A/ja
Application granted granted Critical
Publication of JP7610923B2 publication Critical patent/JP7610923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512292A 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター Active JP7610923B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002163A JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383274P 2016-09-02 2016-09-02
US62/383,274 2016-09-02
PCT/US2017/049959 WO2018045347A1 (en) 2016-09-02 2017-09-01 Methods and vectors for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002163A Division JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Publications (3)

Publication Number Publication Date
JP2019529385A JP2019529385A (ja) 2019-10-17
JP2019529385A5 true JP2019529385A5 (cg-RX-API-DMAC7.html) 2020-09-17
JP7610923B2 JP7610923B2 (ja) 2025-01-09

Family

ID=61309371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019512292A Active JP7610923B2 (ja) 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Country Status (9)

Country Link
US (1) US20190192693A1 (cg-RX-API-DMAC7.html)
EP (1) EP3506930A4 (cg-RX-API-DMAC7.html)
JP (2) JP7610923B2 (cg-RX-API-DMAC7.html)
CN (1) CN110121356A (cg-RX-API-DMAC7.html)
AU (2) AU2017318717B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004353A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035628A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019002518A (cg-RX-API-DMAC7.html)
WO (1) WO2018045347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP3655001A4 (en) * 2017-07-17 2021-04-28 Spark Therapeutics, Inc. Apheresis methods and uses
FI3814513T3 (fi) * 2018-06-28 2025-05-28 Univ North Carolina Chapel Hill Optimoidut cln5-geenit ja -ilmentymiskasetit sekä niiden käyttö
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
IL282808B2 (en) * 2018-11-14 2025-02-01 Regenxbio Inc Gene therapy for neural ceroid lipofuscinosis
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療
CA3129672A1 (en) 2019-02-22 2020-08-27 The Trustees Of The University Of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
US20220348638A1 (en) * 2019-09-24 2022-11-03 The J. David Gladstone Institutes, a testamentary trust estabilished under the Will of J. David Glad Method of targeting neuronal apoe to treat a neurocognitive disorder
CA3157864A1 (en) * 2019-10-16 2021-04-22 Cornell University Gene therapy for alzheimer's disease
WO2022072888A1 (en) * 2020-10-01 2022-04-07 Sangamo Therapeutics, Inc. Methods of detecting anti-aav antibodies
CN112852881B (zh) * 2021-02-09 2023-08-15 南京贝思奥生物科技有限公司 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法
TW202426479A (zh) * 2022-10-10 2024-07-01 美商星火治療公司 Apoe基因療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
ES2786078T3 (es) * 2012-05-18 2020-10-08 Univ Iowa Res Found Métodos y composiciones para tratar depósitos amiloides
EP3024497B1 (en) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
KR20160079891A (ko) * 2013-11-20 2016-07-06 유니버시티 오브 아이오와 리써치 파운데이션 아밀로이드 침착의 치료를 위한 방법 및 조성물
WO2016134375A1 (en) * 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases

Similar Documents

Publication Publication Date Title
JP2019529385A5 (cg-RX-API-DMAC7.html)
ES2897508T3 (es) Variantes de virus adenoasociados y métodos de uso de las mismas
JP2020527333A5 (cg-RX-API-DMAC7.html)
J Dismuke et al. Biosafety of recombinant adeno-associated virus vectors
JP2016503405A5 (cg-RX-API-DMAC7.html)
CN107083400A (zh) 神经退行性疾病的基因治疗
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
HRP20231077T1 (hr) Genska terapija za pigmentni retinitis
JP2017509632A5 (cg-RX-API-DMAC7.html)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2020519629A5 (cg-RX-API-DMAC7.html)
JP2017529395A5 (cg-RX-API-DMAC7.html)
JPWO2020106916A5 (cg-RX-API-DMAC7.html)
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
IL292264B1 (en) Aav transfer cassette
JP2020509786A5 (cg-RX-API-DMAC7.html)
JPWO2019152609A5 (cg-RX-API-DMAC7.html)
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
JPWO2021053222A5 (cg-RX-API-DMAC7.html)
HRP20220199T1 (hr) Postupak genetskog liječenja korištenjem virusa aav-xbp1s/gfp i njegova uporaba u prevenciji i liječenju amiotrofične lateralne skleroze
JPWO2021076911A5 (cg-RX-API-DMAC7.html)
US20220213450A1 (en) Optimized sumf1 genes and expression cassettes and their use
US20250269066A1 (en) Gene therapy
US12480098B1 (en) Adeno-associated virus variant